Int J Oncol 61: 106, 2022; DOI: 10.3892/ijo.2022.5396
Subsequently to the publication of the above article, the authors alerted us to the fact that the data shown in Fig. 8I (for the 'Sh-CN / 0' panel) on p. 11 were mistakenly selected from those data belonging to the experiments shown in Fig. 7H (the 'Sh-CN / 0' panel) of this paper during the final assembly of the figures for review. Note that this error did not affect the conclusions reported in this paper, as both Fig. 7H ('Sh-CN / 0') and Fig. 8I ('Sh-CN / 0') show negative controls of the Comet assay, with no obvious trailing.
Figure 8.
Inhibition of RAD51AP1 overcomes 5-FU-resistance in colorectal cancer cells. (A) Western blot analysis of RAD51AP1 in control and RAD51AP1-KD HCT-8R cells. (B) Cell survival assay in control and RAD51AP1-KD HCT-8R cells. (C) Morphological analysis of control and RAD51AP1-KD HCT-8R cells with 60 µg/ml 5-FU treatment for 48 h. (D) Knockdown of RAD51AP1 promotes apoptosis in HCT-8R cells with 5-FU treatment. (E) Silencing of RAD51AP1 induces caspase-3 and Bax expression in HCT-8R cells following 5-FU treatment. (F) Western blotting to determine γ-H2AX levels in control and RAD51AP1-KD HCT-8R cells following 5-FU treatments for 4 h. (G and H) Immunofluorescence staining of γ-H2AX foci and 53BP1 foci in different cells treated 5-FU for 4 h. (I) Comet assay of RAD51AP1-KD and control HCT-8R cells treated with or without 5-FU (60 µg/ml) for 12 h. *P<0.05, **P<0.01 and ***P<0.001. RAD51AP1, RAD51 associated Protein 1; 5-FU, 5-fluorouracil; KD, knockdown; HCT-8R, 5-FU-resistant HCT-8 cells; sh-, small hairpin; CN, control.
The revised version of Fig. 8, showing the correct data for the 'Sh-CN / 0' panel in Fig. 8I, is shown on the next page. The authors are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish a Corrigendum, and all the authors agree with its publication. Furthermore, the authors apologize to the readership for any inconvenience caused.